Business Standard

As markets rally, MFs pump in cash

Not only FIIs, but domestic fund managers too, dip into their corpus to invest in the rally

Related News

As the fortunes of the markets took a turn for the better in the beginning of 2012, managers of the country's largest jumped into the fray, pumping in money and reducing their cash holdings.

In January, when the market moved up by double digits, majority of the top ten schemes held less than five per cent of their total assets in cash or cash equivalent. Some even reduced their cash position to below one per cent, despite rising redemptions from equity schemes.

These include HDFC Top 200, HDFC Equity, Reliance Growth, Franklin India Bluechip, UTI Dividend, ICICI Prudential Focused Bluechip and DSP BlackRock Top 100 Equity Regular. All put together, these schemes hold around 30 per cent of the industry's overall equity assets of around Rs 1.8 lakh crore.



Prashant Jain, chief investment officer at the country's largest fund house HDFC Mutual Fund, says, "We chose to invest in this market. Though there are redemptions but it is merely around 1.5 per cent of the industry's overall equity assets." The fund house's two largest equity schemes, which are the industry's largest, too, were over 99 per cent invested as on January 31.

According to Sandesh Kirkire, chief executive officer of Kotak Mutual Fund, "There is an overall change in sentiments. Globally too, investors' sentiments are positive and confidence has returned. As markets have rallied, fund managers have deployed the accumulated cash in the markets."

This holds true. In November last year the largest of the equity schemes were sitting on a cash of around eight per cent. And in December, the falling markets bottomed out only to see a sharp rise in the following months.

"This is a strong rally and I do not think there would be a major trend reversal. Fundamentally, the scenario is changing," adds Sadanand Shetty, senior equity fund manager at Taurus Mutual Fund. "There was an initial apprehension when markets rallied five per cent. But when it gained consistently further we did not want to miss the rally and pumped in money," he explains.

According to industry equity heads during such times funds need to perform and maintain ranking. "And it cannot happen if cash holdings remain high," says an equity head. Over the last three months, several categories of equity funds, which include diversified and thematic funds too, have given returns in the range of six to 15 per cent.

For instance, bank equity funds have returned as high as 22 per cent while mid- and small-cap funds gave a return of 13-15 per cent against 13 per cent rise in benchmark indices.

However, so far this year, the fund industry has remained a net seller in the markets with shares worth Rs 4,200 crore being sold. Selling has intensified in February with sales worth f Rs 2,300 crore.

Industry officials say they are eyeing three major upcoming events - the outcome of the UP elections, and the Budget. These factors will play an important role in deciding the direction of the markets in the coming months, they say.

Read more on:   
|
|
|
|
|
|
|
|
|

Read More

Budget holds out little cheer for MF industry

Proposal to raise dividend distribution tax on debt funds disappoints

Quick Links

Market News

Markets rise on ECB tide

World markets rallied on Friday after the European Central Bank decided on Thursday to pump a little over about euro 1 trillion to revive the ...

ECB's QE unlikely to result in widespread gains for all asset classes

Cheap money to seek high-yielding assets; prices of others like industrial metals, gold could settle

Sensex records sharpest seven-day rally since 2009

The Sensex surged 273 points on Friday to close at 29,278.84, and has rallied 1,932 points in the past seven trading days since January 15

Gold imports came to halt as discounts widened

High discounts are due to huge carry over stock of gold imported in November

GSK Pharma, select MNC stocks gain as Sebi eases delisting norm

In intra-day trade, GSK Pharma gained as much as 12% and ended 6.4% higher at Rs 3,347.45

 

Back to Top